COZAAR 25 MG
LOSARTAN POTASSIUM : 25 MG · DIN 02182815 · ORGANON CANADA INC.
Health Canada status: MARKETED
What is COZAAR?
COZAAR 25 MG contains LOSARTAN POTASSIUM : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02182815, held by ORGANON CANADA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is COZAAR used for?
Treatment of essential hypertension; hypertension with left ventricular hypertrophy; type 2 diabetic patients with proteinuria and hypertension to delay renal disease progression.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is COZAAR called?
The same molecule, LOSARTAN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Losartan Medical Valley | Latin | Sweden |
| Losartan Krka | Latin | Sweden |
| Losartan Teva | Latin | Sweden |
| Losartan/Hydrochlorothiazide Krka | Latin | Sweden |
| Losartan Viatris | Latin | Sweden |
| Losartan/Hydrochlorothiazide Medical Valley | Latin | Sweden |
| LOSARTAN GT | Latin | Morocco |
| Losartan STADA | Latin | Sweden |
| Losartan/Hydrochlorothiazide Teva | Latin | Sweden |
| ANGINIB | Latin | Morocco |
| LACINE | Latin | Morocco |
| Losarstad Comp | Latin | Sweden |
| Losartan Sandoz | Latin | Sweden |
| Losartan/Hydrochlorothiazide STADA | Latin | Sweden |
| Marozid | Latin | Sweden |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02182815 |
|---|---|
| Brand name | COZAAR |
| Generic / active ingredient | LOSARTAN POTASSIUM : 25 MG |
| Manufacturer | ORGANON CANADA INC. |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09CA01 LOSARTAN |
| AHFS class | 24:32.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Feb-2022 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02182815 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2182815 |
| Brand name | COZAAR |
| Active ingredient / INN | LOSARTAN POTASSIUM : 25 MG |
| ATC code | C09CA01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C09 |
| AHFS class | 24:32.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | ORGANON CANADA INC. |
How is it administered?
Hypertension: Usually 50-100 mg once daily. Type 2 Diabetes with proteinuria: 50-100 mg once daily. Hepatic impairment/volume depletion: Consider 25 mg starting dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content truncated), though typically room temperature.
How is it supplied?
25 mg: Bottles of 100; 50 mg and 100 mg: Blister packages of 30 tablets.
Which pack is which?
| Strength on the label | 25 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | 25 mg: Bottles of 100; 50 mg and 100 mg: Blister packages of 30 tablets. |
| Storage | Not explicitly detailed in provided text (Section 11 header present but content truncated), though typically room temperature. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity; Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 ml/min/1.73m2).
Warnings and precautions
Fetal toxicity; Hypotension (especially in volume-depleted patients); Renal function impairment; Hyperkalemia; Intestinal angioedema; Anaphylactic reactions.
Is LOSARTAN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09CA01 LOSARTAN. 27 of 81 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-LOSARTAN | 100.0 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02403358 |
| AURO-LOSARTAN | 25.0 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02403323 |
| AURO-LOSARTAN | 50.0 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02403331 |
| COZAAR | 100 MG | TABLET | ORGANON CANADA INC. | MARKETED | DIN 02182882 |
| COZAAR | 50 MG | TABLET | ORGANON CANADA INC. | MARKETED | DIN 02182874 |
| JAMP-LOSARTAN | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02398850 |
| JAMP-LOSARTAN | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02398834 |
| JAMP-LOSARTAN | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02398842 |
| LOSARTAN | 100 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02388812 |
| LOSARTAN | 100 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02388898 |
Who else supplies LOSARTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LOSARTAN appears in 4256 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does LOSARTAN cost around the world?
LOSARTAN is listed on 12 national price registers Nexara tracks, across 303 pack listings published on 11 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 3 | 118 | 03 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 13 | 57 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 16 | 37 | 02 Sep 2026 |
| Greece | producer price (ex-factory) | 19 | 19 | 03 Sep 2026 |
| Morocco | PPV (public price) | 7 | 16 | 05 Sep 2026 |
| South Africa | single exit price | 16 | 16 | 01 Sep 2026 |
| Belgium | public | 12 | 12 | 01 Sep 2026 |
| Hungary | producer price (ex-factory) | 12 | 12 | 03 Sep 2026 |
| Slovakia | categorised final price | 5 | 8 | 02 Sep 2026 |
| Romania | max producer price | 3 | 4 | 03 Sep 2026 |
| United Kingdom | hospital | 3 | 3 | 31 Aug 2026 |
| Spain | PVP con IVA (public price) | 1 | 1 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.